Trial Profile
Phase I trial of RG 012 as a potential therapy for Alport syndrome.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2015
Price :
$35
*
At a glance
- Drugs Lademirsen (Primary)
- Indications Nephritis
- Focus Adverse reactions; First in man
- Sponsors Regulus Therapeutics
- 05 Nov 2015 Status changed from recruiting to completed, according to a Regulus Therapeutics media release.
- 04 Aug 2015 Results are expected to be reported in the second half of 2015, according to a Regulus Therapeutics media release.
- 04 Jun 2015 Status changed from planning to recruiting according to a Regulus Therapeutics media release.